Side-by-side · Research reference
CrystagenvsTesamorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED12/40 cited
BFDA-ApprovedFlagship27/68 cited
Crystagen
Khavinson Bioregulator · Immune-Thymic
SQ · Protocol variable
Tesamorelin
GHRH Analogue · FDA-Approved
SQ · Abdomen · Once Daily
01Mechanism of Action
Parameter
Crystagen
Tesamorelin
Primary target
B-lymphocytes in splenic tissueСhervyakova 2014
Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010
Pathway
B-cell activation → Immune modulation during agingСhervyakova 2014
GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007
Downstream effect
B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014
Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010
Feedback intact?
Unknown — bioregulator mechanism not fully characterized
Yes — physiological pulsatility preserved
Origin
Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series
Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010
02Dosage Protocols
Parameter
Crystagen
Tesamorelin
Standard dose
Not standardized — variable protocols
Russian bioregulator literature does not specify unified human dosing.
2 mg / dayEGRIFTA® (tesamorelin for inje 2010
FDA-approved protocol.
Route
Subcutaneous (presumed from bioregulator class)
—
Frequency
Unknown — bioregulator protocols variable
Once daily (morning or pre-sleep)
Aligns with natural GH pulse.
Duration
Unknown — chronic administration presumed in animal models
12–52 weeks
VAT returns within months of stopping.
Half-life
Not reported
~26 min (plasma)EGRIFTA® (tesamorelin for inje 2010
Modified vs native GHRH (7 min t½).
Reconstitution
—
Sterile water per labeling
Preserved at 2–8 °C after reconstitution.
Timing
—
Empty stomach, pre-sleep preferred
03Metabolic / Fat Loss Evidence
Parameter
Crystagen
Tesamorelin
Primary fat target
—
Visceral adipose tissue (VAT) — abdominal
Effect on lean mass
—
Modest lean mass preservation / slight increase
Effect reversibility
—
VAT returns within months of stopping
Key publication
—
Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007Falutz 2010EGRIFTA® (tesamorelin for inje 2010
04Side Effects & Safety
Parameter
Crystagen
Tesamorelin
Published adverse events
None reported in available animal literature
—
Human safety data
Absent — no controlled human trials identified
—
Autoimmune considerations
Theoretical concern with B-cell modulators in predisposed individuals
—
Injection site reaction
—
Erythema, pruritus, redness (common)
Fluid retention / Edema
—
Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)
IGF-1 elevation
—
Dose-dependent; supraphysiological levels = discontinue
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010
Antibody formation
—
~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018
GI symptoms
—
Nausea, diarrhea (mild, transient)
Absolute Contraindications
Crystagen
- ·Active autoimmune disease (theoretical)
Tesamorelin
- ·Active malignancy or history of treated cancer
- ·Pregnancy
- ·Hypersensitivity to tesamorelin or mannitol
- ·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)
Relative Contraindications
Crystagen
- ·Pregnancy / lactation (no data)
- ·Active B-cell malignancies
Tesamorelin
- ·Untreated diabetes (monitor HbA1c)
- ·Severe carpal tunnel syndrome
- ·Acute critical illness
05Administration Protocol
Parameter
Crystagen
Tesamorelin
1. Route
Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.
Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.
2. Reconstitution
Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.
Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.
3. Timing
Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.
Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.
4. Storage
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.
5. Needle
—
27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.
06Stack Synergy
Crystagen
+ Vilon
Multi-pathwayVilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.
- Crystagen
- Dose unknown · SQ
- Vilon
- Dose unknown · SQ
- Frequency
- Protocol variable
- Primary benefit
- Broader thymic-immune coverage (T-cell + B-cell)
Tesamorelin
+ Ipamorelin
StrongTesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.
- Tesamorelin
- 2 mg SQ · evening
- Ipamorelin
- 200–300 mcg SQ · same injection
- Frequency
- Once daily, pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep quality